Calquence 100 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26F9NK2
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,580
Award facts
- Contract value 100% obligated
- $23,579.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $23,579.88 to AmerisourceBergen Drug Corp for the supply of Calquence 100 mg tablets (60-count) with a completion date of February 19, 2026. This firm fixed-price delivery order was awarded on January 28, 2026, on a non-set-aside, competitive basis. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle through December 2026 that serves as the primary mechanism for supplying pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The company maintains a comprehensive portfolio of pharmaceutical deliveries with the DLA and holds significant contract vehicles enabling it to supply an extensive range of products including brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. Calquence (acalabrutinib) is a targeted cancer therapy, reflecting the company's capabilities in delivering specialized oncology pharmaceuticals to federal healthcare beneficiaries.
Quick answers
Who was awarded contract SPE2DR26F9NK2?
SPE2DR26F9NK2 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26F9NK2 worth?
The government has obligated $23,580 on SPE2DR26F9NK2.
Is contract SPE2DR26F9NK2 an order under another contract?
Yes. SPE2DR26F9NK2 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9NK2 competed?
The extent of competition for SPE2DR26F9NK2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award